Interstitial Lung Disease
📧 Sign up to get email alerts when something new happens for Interstitial Lung Disease.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-06-25EMA Authorised: Nintedanib Accord (nintedanib) — Accord Healthcare S.L.U.
EU authorization of Nintedanib Accord for idiopathic pulmonary fibrosis and related interstitial lung diseases, expanding treatment options …
-
EMA approval · 2026-01-06EMA Authorised: Ofev (nintedanib) — Boehringer Ingelheim International GmbH
The European Medicines Agency authorised a label expansion for Ofev (nintedanib) to cover additional interstitial lung diseases, including s…
-
EMA approval · 2025-12-19EMA Authorised: Pirfenidone Viatris (Pirfenidone) — Viatris Limited
EMA authorised Pirfenidone Viatris as a generic version of pirfenidone for idiopathic pulmonary fibrosis in the European Union, expanding ac…
-
EMA approval · 2025-09-05EMA Authorised: Nintedanib Viatris (nintedanib) — Viatris Limited
The European Medicines Agency authorised a generic version of nintedanib (Nintedanib Viatris) for idiopathic pulmonary fibrosis and related …
-
EMA approval · 2025-08-29EMA Authorised: Nintedanib Accord (nintedanib) — Accord Healthcare S.L.U.
The EMA authorised Nintedanib Accord for indications including Idiopathic Pulmonary Fibrosis, interstitial lung diseases, systemic sclerosis…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS approval · 2024-12-10Clinical Trial Update: An Expanded Access Program to Provide Nintedanib to Patients With Non-IPF ILD Who Have no Alternative Treatment Possibilities
Expanded access program to provide Nintedanib to patients with non-IPF interstitial lung disease who have no alternative treatment possibili…